Coronavirus: Remdesivir allocated till May 23 to States/UTs, says Gowda

The Ministry of Chemicals and Fertilizers has made adequate allocation of Remdesivir injection till May 23 for the treatment of Covid patients, it said.

Coronavirus: Remdesivir allocated till May 23 to States/UTs, says Gowda
IANS New Delhi
2 min read Last Updated : May 16 2021 | 5:04 PM IST

The Ministry of Chemicals and Fertilizers has made adequate allocation of Remdesivir injection till May 23 for the treatment of Covid patients, it said.

Considering the requirement of Remdesivir in every state and ensuring its adequate availability, Union Minister of Chemicals & Fertilisers D.V Sadananda Gowda on Sunday announced the allocation of Remdesivir and said substantial increase has been made in overall production and allocation of the drug, crucial in treatment of Covid patients.

In a letter to all States by Department of Pharmaceuticals and Ministry of Health and Family Welfare, it was mentioned that in continuation of the allocation plan of Remdesivir drug for the period -- April 21 to May 16, 2021 communicated by D.O on May 7 2021, an updated allocation plan valid for the period -- April 21 to May May 21, 2021 is prepared jointly by the Department of Pharmaceuticals and Ministry of Health and Family Welfare.

The allotment has been made for the States/UTs and they have been asked to monitor proper distribution covering government and private hospitals as appropriate and in line with judicious use.

State governments/UTs have been advised to place adequate purchase orders with the marketing companies immediately, if they have not already done so, for the quantity that they want to purchase out of allocation for the State/UT as per supply chain in close coordination with liaison officers of the companies. The coordination with private distribution channel in the state could also be made.

--IANS

miz/skp/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusRemdesivirD V Sadananda Gowda

First Published: May 16 2021 | 4:50 PM IST

Next Story